# Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults

> **NCT04620291** · PHASE1 · UNKNOWN · sponsor: **United BioPharma** · enrollment: 18 (estimated)

## Conditions studied

- HIV-1-infection

## Interventions

- **BIOLOGICAL:** UB-421 SC

## Key facts

- **NCT ID:** NCT04620291
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620291, "Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation in HIV Infected Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04620291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*